OA12076A - Method and compositions for treating pulmonary diseases. - Google Patents

Method and compositions for treating pulmonary diseases. Download PDF

Info

Publication number: OA12076A
Authority: OA; OAPI
Prior art keywords: pde; rolipram; pde4; asthma; compounds
Prior art date: 1999-11-02

Application number

OA1200200124A

Other languages

English (en)

Inventor

Peter N Goodfellow

Richard Nieman

Theodore J Torphy

Original Assignee

Smithkline Beecham Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-11-02

Filing date

2000-11-01

Publication date

2006-05-04

2000-11-01 Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp

2006-05-04 Publication of OA12076A publication Critical patent/OA12076A/en

Links

208000019693 Lung disease Diseases 0.000 title claims abstract description 13
238000000034 method Methods 0.000 title claims description 9
239000000203 mixture Substances 0.000 title description 13
229940123932 Phosphodiesterase 4 inhibitor Drugs 0.000 claims abstract description 17
239000002587 phosphodiesterase IV inhibitor Substances 0.000 claims abstract description 17
239000003246 corticosteroid Substances 0.000 claims abstract description 8
230000003110 anti-inflammatory effect Effects 0.000 claims abstract description 6
VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 claims description 6
WOFMFGQZHJDGCX-ZULDAHANSA-N mometasone furoate Chemical compound O([C@]1([C@@]2(C)C[C@H](O)[C@]3(Cl)[C@@]4(C)C=CC(=O)C=C4CC[C@H]3[C@@H]2C[C@H]1C)C(=O)CCl)C(=O)C1=CC=CO1 WOFMFGQZHJDGCX-ZULDAHANSA-N 0.000 claims description 6
150000003431 steroids Chemical class 0.000 claims description 6
229960004436 budesonide Drugs 0.000 claims description 5
229960002744 mometasone furoate Drugs 0.000 claims description 5
229940092705 beclomethasone Drugs 0.000 claims description 4
NBMKJKDGKREAPL-DVTGEIKXSA-N beclomethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O NBMKJKDGKREAPL-DVTGEIKXSA-N 0.000 claims description 4
229960003957 dexamethasone Drugs 0.000 claims description 4
UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims description 4
229960000676 flunisolide Drugs 0.000 claims description 4
MIXMJCQRHVAJIO-TZHJZOAOSA-N qk4dys664x Chemical compound O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O MIXMJCQRHVAJIO-TZHJZOAOSA-N 0.000 claims description 4
YNDXUCZADRHECN-JNQJZLCISA-N triamcinolone acetonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O YNDXUCZADRHECN-JNQJZLCISA-N 0.000 claims description 4
CFBUZOUXXHZCFB-UHFFFAOYSA-N 4-cyano-4-(3-cyclopentyloxy-4-methoxyphenyl)-1-cyclohexanecarboxylic acid Chemical compound COC1=CC=C(C2(CCC(CC2)C(O)=O)C#N)C=C1OC1CCCC1 CFBUZOUXXHZCFB-UHFFFAOYSA-N 0.000 claims description 3
229960002714 fluticasone Drugs 0.000 claims description 3
MGNNYOODZCAHBA-GQKYHHCASA-N fluticasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(O)[C@@]2(C)C[C@@H]1O MGNNYOODZCAHBA-GQKYHHCASA-N 0.000 claims description 3
229960002117 triamcinolone acetonide Drugs 0.000 claims description 3
238000004519 manufacturing process Methods 0.000 claims 1
208000006673 asthma Diseases 0.000 abstract description 23
208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 abstract description 2
150000001875 compounds Chemical class 0.000 description 24
230000000694 effects Effects 0.000 description 21
230000027455 binding Effects 0.000 description 20
229950005741 rolipram Drugs 0.000 description 18
102000011017 Type 4 Cyclic Nucleotide Phosphodiesterases Human genes 0.000 description 17
108010037584 Type 4 Cyclic Nucleotide Phosphodiesterases Proteins 0.000 description 17
MSYGAHOHLUJIKV-UHFFFAOYSA-N 3,5-dimethyl-1-(3-nitrophenyl)-1h-pyrazole-4-carboxylic acid ethyl ester Chemical compound CC1=C(C(=O)OCC)C(C)=NN1C1=CC=CC([N+]([O-])=O)=C1 MSYGAHOHLUJIKV-UHFFFAOYSA-N 0.000 description 16
239000003814 drug Substances 0.000 description 15
HJORMJIFDVBMOB-UHFFFAOYSA-N rolipram Chemical compound COC1=CC=C(C2CC(=O)NC2)C=C1OC1CCCC1 HJORMJIFDVBMOB-UHFFFAOYSA-N 0.000 description 14
229940079593 drug Drugs 0.000 description 12
101100296719 Caenorhabditis elegans pde-4 gene Proteins 0.000 description 10
230000003197 catalytic effect Effects 0.000 description 8
239000003112 inhibitor Substances 0.000 description 8
208000024891 symptom Diseases 0.000 description 7
102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 6
108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 6
238000004458 analytical method Methods 0.000 description 6
210000004027 cell Anatomy 0.000 description 6
230000005764 inhibitory process Effects 0.000 description 6
HJORMJIFDVBMOB-LBPRGKRZSA-N (-)-rolipram Chemical compound COC1=CC=C([C@H]2CC(=O)NC2)C=C1OC1CCCC1 HJORMJIFDVBMOB-LBPRGKRZSA-N 0.000 description 5
UCHDWCPVSPXUMX-TZIWLTJVSA-N Montelukast Chemical compound CC(C)(O)C1=CC=CC=C1CC[C@H](C=1C=C(\C=C\C=2N=C3C=C(Cl)C=CC3=CC=2)C=CC=1)SCC1(CC(O)=O)CC1 UCHDWCPVSPXUMX-TZIWLTJVSA-N 0.000 description 5
238000003556 assay Methods 0.000 description 5
229960005127 montelukast Drugs 0.000 description 5
108010044467 Isoenzymes Proteins 0.000 description 4
TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 4
210000005091 airway smooth muscle Anatomy 0.000 description 4
239000002775 capsule Substances 0.000 description 4
229920001684 low density polyethylene Polymers 0.000 description 4
239000000902 placebo Substances 0.000 description 4
229940068196 placebo Drugs 0.000 description 4
230000036515 potency Effects 0.000 description 4
108090000623 proteins and genes Proteins 0.000 description 4
239000000725 suspension Substances 0.000 description 4
102000004190 Enzymes Human genes 0.000 description 3
108090000790 Enzymes Proteins 0.000 description 3
230000004913 activation Effects 0.000 description 3
102000030621 adenylate cyclase Human genes 0.000 description 3
108060000200 adenylate cyclase Proteins 0.000 description 3
238000013459 approach Methods 0.000 description 3
230000008859 change Effects 0.000 description 3
239000003795 chemical substances by application Substances 0.000 description 3
201000010099 disease Diseases 0.000 description 3
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
229940125369 inhaled corticosteroids Drugs 0.000 description 3
230000002401 inhibitory effect Effects 0.000 description 3
210000001616 monocyte Anatomy 0.000 description 3
239000002294 steroidal antiinflammatory agent Substances 0.000 description 3
ZOOGRGPOEVQQDX-UUOKFMHZSA-N 3',5'-cyclic GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-UUOKFMHZSA-N 0.000 description 2
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
KUVIULQEHSCUHY-XYWKZLDCSA-N Beclometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COC(=O)CC)(OC(=O)CC)[C@@]1(C)C[C@@H]2O KUVIULQEHSCUHY-XYWKZLDCSA-N 0.000 description 2
IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 2
108010010803 Gelatin Proteins 0.000 description 2
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
241000124008 Mammalia Species 0.000 description 2
240000004808 Saccharomyces cerevisiae Species 0.000 description 2
IVOMOUWHDPKRLL-UHFFFAOYSA-N UNPD107823 Natural products O1C2COP(O)(=O)OC2C(O)C1N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-UHFFFAOYSA-N 0.000 description 2
239000002253 acid Substances 0.000 description 2
229950000210 beclometasone dipropionate Drugs 0.000 description 2
229940098032 beconase Drugs 0.000 description 2
230000008901 benefit Effects 0.000 description 2
229940124748 beta 2 agonist Drugs 0.000 description 2
239000000872 buffer Substances 0.000 description 2
239000000969 carrier Substances 0.000 description 2
238000002648 combination therapy Methods 0.000 description 2
229960001334 corticosteroids Drugs 0.000 description 2
229940095074 cyclic amp Drugs 0.000 description 2
125000004122 cyclic group Chemical group 0.000 description 2
238000013461 design Methods 0.000 description 2
238000011161 development Methods 0.000 description 2
239000002552 dosage form Substances 0.000 description 2
239000003937 drug carrier Substances 0.000 description 2
KYFWUBJMTHVBIF-QFIPXVFZSA-N dsstox_cid_27248 Chemical compound N([C@@H]1N=C(C=2C=3N(C1=O)CCC=3C=C(C=2)C)C=1C=CC=CC=1)C(=O)C1=CC=NC=C1 KYFWUBJMTHVBIF-QFIPXVFZSA-N 0.000 description 2
WMWTYOKRWGGJOA-CENSZEJFSA-N fluticasone propionate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(OC(=O)CC)[C@@]2(C)C[C@@H]1O WMWTYOKRWGGJOA-CENSZEJFSA-N 0.000 description 2
238000009472 formulation Methods 0.000 description 2
230000006870 function Effects 0.000 description 2
229920000159 gelatin Polymers 0.000 description 2
239000008273 gelatin Substances 0.000 description 2
239000007903 gelatin capsule Substances 0.000 description 2
235000019322 gelatine Nutrition 0.000 description 2
235000011852 gelatine desserts Nutrition 0.000 description 2
239000005556 hormone Substances 0.000 description 2
229940088597 hormone Drugs 0.000 description 2
230000006872 improvement Effects 0.000 description 2
239000003446 ligand Substances 0.000 description 2
239000007788 liquid Substances 0.000 description 2
229910001629 magnesium chloride Inorganic materials 0.000 description 2
210000000440 neutrophil Anatomy 0.000 description 2
239000003921 oil Substances 0.000 description 2
235000019198 oils Nutrition 0.000 description 2
239000000651 prodrug Substances 0.000 description 2
229940002612 prodrug Drugs 0.000 description 2
102000004169 proteins and genes Human genes 0.000 description 2
230000002685 pulmonary effect Effects 0.000 description 2
230000004648 relaxation of smooth muscle Effects 0.000 description 2
230000004044 response Effects 0.000 description 2
MNDBXUUTURYVHR-UHFFFAOYSA-N roflumilast Chemical compound FC(F)OC1=CC=C(C(=O)NC=2C(=CN=CC=2Cl)Cl)C=C1OCC1CC1 MNDBXUUTURYVHR-UHFFFAOYSA-N 0.000 description 2
150000003839 salts Chemical class 0.000 description 2
239000000243 solution Substances 0.000 description 2
238000004611 spectroscopical analysis Methods 0.000 description 2
239000000758 substrate Substances 0.000 description 2
239000006188 syrup Substances 0.000 description 2
235000020357 syrup Nutrition 0.000 description 2
239000003826 tablet Substances 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
210000001519 tissue Anatomy 0.000 description 2
PYHRZPFZZDCOPH-QXGOIDDHSA-N (S)-amphetamine sulfate Chemical compound [H+].[H+].[O-]S([O-])(=O)=O.C[C@H](N)CC1=CC=CC=C1.C[C@H](N)CC1=CC=CC=C1 PYHRZPFZZDCOPH-QXGOIDDHSA-N 0.000 description 1
HJPRDDKCXVCFOH-UHFFFAOYSA-N 1,3-dibutyl-7-(2-oxopropyl)purine-2,6-dione Chemical compound O=C1N(CCCC)C(=O)N(CCCC)C2=C1N(CC(C)=O)C=N2 HJPRDDKCXVCFOH-UHFFFAOYSA-N 0.000 description 1
SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 description 1
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
MRHCSNNEUHXNIC-UHFFFAOYSA-N 9-benzylpurin-6-amine Chemical compound C1=NC=2C(N)=NC=NC=2N1CC1=CC=CC=C1 MRHCSNNEUHXNIC-UHFFFAOYSA-N 0.000 description 1
OIRDTQYFTABQOQ-KQYNXXCUSA-N Adenosine Natural products C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 1
102000009027 Albumins Human genes 0.000 description 1
108010088751 Albumins Proteins 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
235000003911 Arachis Nutrition 0.000 description 1
244000105624 Arachis hypogaea Species 0.000 description 1
208000037874 Asthma exacerbation Diseases 0.000 description 1
206010003557 Asthma exercise induced Diseases 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
239000002126 C01EB10 - Adenosine Substances 0.000 description 1
QGBIFMJAQARMNQ-QISPFCDLSA-N C1([C@@H](F)C2)=CC(=O)CC[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3O[C@@H](CCC)O[C@@]3(SC)[C@@]2(C)C[C@@H]1O Chemical compound C1([C@@H](F)C2)=CC(=O)CC[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3O[C@@H](CCC)O[C@@]3(SC)[C@@]2(C)C[C@@H]1O QGBIFMJAQARMNQ-QISPFCDLSA-N 0.000 description 1
QWOJMRHUQHTCJG-UHFFFAOYSA-N CC([CH2-])=O Chemical compound CC([CH2-])=O QWOJMRHUQHTCJG-UHFFFAOYSA-N 0.000 description 1
108010001857 Cell Surface Receptors Proteins 0.000 description 1
206010008469 Chest discomfort Diseases 0.000 description 1
208000017667 Chronic Disease Diseases 0.000 description 1
LUKZNWIVRBCLON-GXOBDPJESA-N Ciclesonide Chemical compound C1([C@H]2O[C@@]3([C@H](O2)C[C@@H]2[C@@]3(C[C@H](O)[C@@H]3[C@@]4(C)C=CC(=O)C=C4CC[C@H]32)C)C(=O)COC(=O)C(C)C)CCCCC1 LUKZNWIVRBCLON-GXOBDPJESA-N 0.000 description 1
206010011224 Cough Diseases 0.000 description 1
208000000059 Dyspnea Diseases 0.000 description 1
206010013975 Dyspnoeas Diseases 0.000 description 1
208000004657 Exercise-Induced Asthma Diseases 0.000 description 1
206010020751 Hypersensitivity Diseases 0.000 description 1
206010061218 Inflammation Diseases 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
240000007472 Leucaena leucocephala Species 0.000 description 1
235000010643 Leucaena leucocephala Nutrition 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
FQISKWAFAHGMGT-SGJOWKDISA-M Methylprednisolone sodium succinate Chemical compound [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC([O-])=O)CC[C@H]21 FQISKWAFAHGMGT-SGJOWKDISA-M 0.000 description 1
206010028813 Nausea Diseases 0.000 description 1
235000019483 Peanut oil Nutrition 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
235000021355 Stearic acid Nutrition 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
206010047700 Vomiting Diseases 0.000 description 1
206010047924 Wheezing Diseases 0.000 description 1
HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
CDKNUFNIFGPFSF-AYVLZSQQSA-N [(8s,9s,10r,11s,13s,14s,17r)-11-hydroxy-10,13-dimethyl-3-oxo-17-(2-propanoylsulfanylacetyl)-2,6,7,8,9,11,12,14,15,16-decahydro-1h-cyclopenta[a]phenanthren-17-yl] butanoate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)CSC(=O)CC)(OC(=O)CCC)[C@@]1(C)C[C@@H]2O CDKNUFNIFGPFSF-AYVLZSQQSA-N 0.000 description 1
230000009471 action Effects 0.000 description 1
239000012190 activator Substances 0.000 description 1
239000013543 active substance Substances 0.000 description 1
229960005305 adenosine Drugs 0.000 description 1
UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 description 1
239000000556 agonist Substances 0.000 description 1
230000007815 allergy Effects 0.000 description 1
239000005557 antagonist Substances 0.000 description 1
230000001430 anti-depressive effect Effects 0.000 description 1
239000000935 antidepressant agent Substances 0.000 description 1
229940005513 antidepressants Drugs 0.000 description 1
239000008365 aqueous carrier Substances 0.000 description 1
210000003651 basophil Anatomy 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
210000004556 brain Anatomy 0.000 description 1
229940124630 bronchodilator Drugs 0.000 description 1
239000000168 bronchodilator agent Substances 0.000 description 1
OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
230000007248 cellular mechanism Effects 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
235000010980 cellulose Nutrition 0.000 description 1
CFBUZOUXXHZCFB-OYOVHJISSA-N chembl511115 Chemical compound COC1=CC=C([C@@]2(CC[C@H](CC2)C(O)=O)C#N)C=C1OC1CCCC1 CFBUZOUXXHZCFB-OYOVHJISSA-N 0.000 description 1
208000023819 chronic asthma Diseases 0.000 description 1
229960003728 ciclesonide Drugs 0.000 description 1
239000003086 colorant Substances 0.000 description 1
239000002131 composite material Substances 0.000 description 1
238000013270 controlled release Methods 0.000 description 1
HJSLFCCWAKVHIW-UHFFFAOYSA-N cyclohexane-1,3-dione Chemical compound O=C1CCCC(=O)C1 HJSLFCCWAKVHIW-UHFFFAOYSA-N 0.000 description 1
229950004687 denbufylline Drugs 0.000 description 1
231100000673 dose–response relationship Toxicity 0.000 description 1
229940112141 dry powder inhaler Drugs 0.000 description 1
201000006549 dyspepsia Diseases 0.000 description 1
230000003028 elevating effect Effects 0.000 description 1
238000005538 encapsulation Methods 0.000 description 1
238000001952 enzyme assay Methods 0.000 description 1
KAQKFAOMNZTLHT-VVUHWYTRSA-N epoprostenol Chemical compound O1C(=CCCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]21 KAQKFAOMNZTLHT-VVUHWYTRSA-N 0.000 description 1
229960001123 epoprostenol Drugs 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
208000024695 exercise-induced bronchoconstriction Diseases 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
229940033835 flonase Drugs 0.000 description 1
XSFJVAJPIHIPKU-XWCQMRHXSA-N flunisolide Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O XSFJVAJPIHIPKU-XWCQMRHXSA-N 0.000 description 1
229960000289 fluticasone propionate Drugs 0.000 description 1
230000002496 gastric effect Effects 0.000 description 1
235000011187 glycerol Nutrition 0.000 description 1
208000024798 heartburn Diseases 0.000 description 1
210000003630 histaminocyte Anatomy 0.000 description 1
229930195733 hydrocarbon Natural products 0.000 description 1
150000002430 hydrocarbons Chemical class 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
230000002779 inactivation Effects 0.000 description 1
230000004054 inflammatory process Effects 0.000 description 1
208000030603 inherited susceptibility to asthma Diseases 0.000 description 1
238000013383 initial experiment Methods 0.000 description 1
239000007972 injectable composition Substances 0.000 description 1
238000002372 labelling Methods 0.000 description 1
239000008101 lactose Substances 0.000 description 1
238000012153 long-term therapy Methods 0.000 description 1
239000007937 lozenge Substances 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
230000004199 lung function Effects 0.000 description 1
210000002540 macrophage Anatomy 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
102000006240 membrane receptors Human genes 0.000 description 1
229960004584 methylprednisolone Drugs 0.000 description 1
230000004048 modification Effects 0.000 description 1
238000012986 modification Methods 0.000 description 1
150000004682 monohydrates Chemical class 0.000 description 1
DPHDSIQHVGSITN-UHFFFAOYSA-N n-(3,5-dichloropyridin-4-yl)-2-[1-[(4-fluorophenyl)methyl]-5-hydroxyindol-3-yl]-2-oxoacetamide Chemical compound C1=C(C(=O)C(=O)NC=2C(=CN=CC=2Cl)Cl)C2=CC(O)=CC=C2N1CC1=CC=C(F)C=C1 DPHDSIQHVGSITN-UHFFFAOYSA-N 0.000 description 1
229940002297 nasacort Drugs 0.000 description 1
229940097496 nasal spray Drugs 0.000 description 1
239000007922 nasal spray Substances 0.000 description 1
229940003691 nasonex Drugs 0.000 description 1
230000008693 nausea Effects 0.000 description 1
239000002858 neurotransmitter agent Substances 0.000 description 1
239000002547 new drug Substances 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
239000004006 olive oil Substances 0.000 description 1
235000008390 olive oil Nutrition 0.000 description 1
229940124624 oral corticosteroid Drugs 0.000 description 1
239000007935 oral tablet Substances 0.000 description 1
229940096978 oral tablet Drugs 0.000 description 1
239000000312 peanut oil Substances 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
238000001050 pharmacotherapy Methods 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
239000000843 powder Substances 0.000 description 1
229960005205 prednisolone Drugs 0.000 description 1
OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
229960004618 prednisone Drugs 0.000 description 1
XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
230000008569 process Effects 0.000 description 1
239000003380 propellant Substances 0.000 description 1
238000000159 protein binding assay Methods 0.000 description 1
229940072266 pulmicort Drugs 0.000 description 1
208000024981 pyrosis Diseases 0.000 description 1
239000011535 reaction buffer Substances 0.000 description 1
238000011160 research Methods 0.000 description 1
206010039083 rhinitis Diseases 0.000 description 1
IXTCZMJQGGONPY-XJAYAHQCSA-N rofleponide Chemical compound C1([C@@H](F)C2)=CC(=O)CC[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3O[C@@H](CCC)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O IXTCZMJQGGONPY-XJAYAHQCSA-N 0.000 description 1
229950004432 rofleponide Drugs 0.000 description 1
229960002586 roflumilast Drugs 0.000 description 1
238000012216 screening Methods 0.000 description 1
230000009291 secondary effect Effects 0.000 description 1
239000008159 sesame oil Substances 0.000 description 1
235000011803 sesame oil Nutrition 0.000 description 1
150000004760 silicates Chemical class 0.000 description 1
239000001488 sodium phosphate Substances 0.000 description 1
229910000162 sodium phosphate Inorganic materials 0.000 description 1
239000007787 solid Substances 0.000 description 1
239000007921 spray Substances 0.000 description 1
238000012289 standard assay Methods 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
239000008117 stearic acid Substances 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
230000001629 suppression Effects 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
235000012222 talc Nutrition 0.000 description 1
238000012360 testing method Methods 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
231100001274 therapeutic index Toxicity 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 1
229940029284 trichlorofluoromethane Drugs 0.000 description 1
RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
238000003828 vacuum filtration Methods 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
238000001262 western blot Methods 0.000 description 1
229910052727 yttrium Inorganic materials 0.000 description 1
239000011701 zinc Substances 0.000 description 1
229910052725 zinc Inorganic materials 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Pulmonology (AREA)
Epidemiology (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

OA1200200124A 1999-11-02 2000-11-01 Method and compositions for treating pulmonary diseases. OA12076A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US16315899P	1999-11-02	1999-11-02

Publications (1)

Publication Number	Publication Date
OA12076A true OA12076A (en)	2006-05-04

Family

ID=22588737

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
OA1200200124A OA12076A (en)	1999-11-02	2000-11-01	Method and compositions for treating pulmonary diseases.

Country Status (29)

Country	Link
EP (1)	EP1225866A4 (fr)
JP (1)	JP2003513028A (fr)
KR (1)	KR20020057988A (fr)
CN (1)	CN1387404A (fr)
AP (1)	AP2002002496A0 (fr)
AR (1)	AR029189A1 (fr)
AU (1)	AU1357501A (fr)
BG (1)	BG106748A (fr)
BR (1)	BR0015270A (fr)
CA (1)	CA2388333A1 (fr)
CO (1)	CO5261512A1 (fr)
CZ (1)	CZ20021512A3 (fr)
DZ (1)	DZ3225A1 (fr)
EA (1)	EA200200518A1 (fr)
EC (1)	ECSP003747A (fr)
HK (1)	HK1049107A1 (fr)
HU (1)	HUP0203152A3 (fr)
IL (1)	IL149367A0 (fr)
MA (1)	MA26841A1 (fr)
MX (1)	MXPA02004350A (fr)
NO (1)	NO20022057L (fr)
OA (1)	OA12076A (fr)
PE (1)	PE20011005A1 (fr)
PL (1)	PL355261A1 (fr)
SK (1)	SK7592002A3 (fr)
TR (1)	TR200201211T2 (fr)
TW (1)	TWI242431B (fr)
WO (1)	WO2001032127A2 (fr)
ZA (1)	ZA200203435B (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IL160271A0 (en)	2001-09-19	2004-07-25	Altana Pharma Ag	Pharmaceutical compositions containing pde4-inhibitors and nsaid
MXPA04003668A (es) *	2001-10-31	2004-07-22	Merck Patent Gmbh	Inhibidores de fosfodiesteresa de tipo 4 y usos de los mismos.
UA82323C2 (uk) *	2002-08-09	2008-04-10	Меда Фарма Гмбх & Ко. Кг	Нова комбінація глюкокортикоїду та pde-інгібітору для лікування респіраторних захворювань, алергічних захворювань, астми та хронічних обструктивних легеневих захворювань
TW200410923A (en) *	2002-10-17	2004-07-01	Ono Pharmaceutical Co	Therapeutic agent for chronic obstructive pulmonary disease
CA2520577A1 (fr) *	2003-03-31	2004-10-14	Kyowa Hakko Kogyo Co., Ltd.	Composition pharmaceutique
US20050026883A1 (en) *	2003-07-31	2005-02-03	Robinson Cynthia B.	Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a PDE-4 inhibitor for treatment of asthma or chronic obstructive pulmonary disease
JPWO2006041121A1 (ja) *	2004-10-13	2008-05-15	協和醗酵工業株式会社	慢性皮膚疾患の治療および／または予防剤
AU2006305620A1 (en) *	2005-10-19	2007-04-26	Ranbaxy Laboratories Limited	Compositions of phosphodiesterase type IV inhibitors
CN102665807A (zh)	2010-01-05	2012-09-12	微剂量治疗技术公司	吸入设备和方法
WO2015063669A1 (fr)	2013-10-30	2015-05-07	Wockhardt Limited	Compositions pharmaceutiques comprenant une combinaison de roflumilast et d'acébrophylline ou de leurs sels pharmaceutiquement acceptables

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PT710109E (pt) *	1993-06-18	2005-01-31	Smithkline Beecham Corp	Metodo para identificar um inibidor de pde iv
DE4332041C2 (de) *	1993-09-21	1997-12-11	Rentschler Arzneimittel	Verwendung von Pentoxifyllin bei bestimmten Lungenerkrankungen
PE44995A1 (es) *	1994-01-27	1995-12-18	Schering Corp	Furoato de mometasona para el tratamiento de las enfermedades pulmonares y de las vias respiratorias
SE9801368D0 (sv) *	1998-04-20	1998-04-20	Astra Ab	New use

2000
- 2000-10-31 AR ARP000105742A patent/AR029189A1/es not_active Application Discontinuation
- 2000-10-31 EC EC2000003747A patent/ECSP003747A/es unknown
- 2000-11-01 SK SK759-2002A patent/SK7592002A3/sk unknown
- 2000-11-01 BR BR0015270-6A patent/BR0015270A/pt not_active IP Right Cessation
- 2000-11-01 CN CN00815265A patent/CN1387404A/zh active Pending
- 2000-11-01 HU HU0203152A patent/HUP0203152A3/hu unknown
- 2000-11-01 IL IL14936700A patent/IL149367A0/xx unknown
- 2000-11-01 AU AU13575/01A patent/AU1357501A/en not_active Abandoned
- 2000-11-01 CZ CZ20021512A patent/CZ20021512A3/cs unknown
- 2000-11-01 OA OA1200200124A patent/OA12076A/en unknown
- 2000-11-01 JP JP2001534335A patent/JP2003513028A/ja active Pending
- 2000-11-01 EP EP00975533A patent/EP1225866A4/fr not_active Withdrawn
- 2000-11-01 AP APAP/P/2002/002496A patent/AP2002002496A0/en unknown
- 2000-11-01 MX MXPA02004350A patent/MXPA02004350A/es unknown
- 2000-11-01 CA CA002388333A patent/CA2388333A1/fr not_active Abandoned
- 2000-11-01 KR KR1020027005609A patent/KR20020057988A/ko not_active Ceased
- 2000-11-01 DZ DZ003225A patent/DZ3225A1/fr active
- 2000-11-01 TR TR2002/01211T patent/TR200201211T2/xx unknown
- 2000-11-01 EA EA200200518A patent/EA200200518A1/ru unknown
- 2000-11-01 PL PL00355261A patent/PL355261A1/xx not_active Application Discontinuation
- 2000-11-01 WO PCT/US2000/030113 patent/WO2001032127A2/fr not_active Ceased
- 2000-11-01 HK HK02109234.5A patent/HK1049107A1/zh unknown
- 2000-11-02 PE PE2000001168A patent/PE20011005A1/es not_active Application Discontinuation
- 2000-11-02 CO CO00083427A patent/CO5261512A1/es not_active Application Discontinuation
- 2000-11-22 TW TW089123039A patent/TWI242431B/zh not_active IP Right Cessation
2002
- 2002-04-30 NO NO20022057A patent/NO20022057L/no not_active Application Discontinuation
- 2002-04-30 ZA ZA200203435A patent/ZA200203435B/xx unknown
- 2002-05-02 MA MA26621A patent/MA26841A1/fr unknown
- 2002-05-29 BG BG106748A patent/BG106748A/xx unknown

Also Published As

Publication number	Publication date
PE20011005A1 (es)	2001-09-28
ECSP003747A (es)	2002-05-23
SK7592002A3 (en)	2002-11-06
MA26841A1 (fr)	2004-12-20
TWI242431B (en)	2005-11-01
ZA200203435B (en)	2003-06-25
CA2388333A1 (fr)	2001-05-10
IL149367A0 (en)	2002-11-10
CN1387404A (zh)	2002-12-25
NO20022057L (no)	2002-06-27
HUP0203152A3 (en)	2004-06-28
AU1357501A (en)	2001-05-14
CZ20021512A3 (cs)	2003-04-16
HUP0203152A2 (hu)	2003-01-28
KR20020057988A (ko)	2002-07-12
JP2003513028A (ja)	2003-04-08
WO2001032127A3 (fr)	2001-12-06
CO5261512A1 (es)	2003-03-31
NO20022057D0 (no)	2002-04-30
DZ3225A1 (fr)	2001-05-10
BR0015270A (pt)	2002-06-18
EP1225866A4 (fr)	2004-04-21
BG106748A (en)	2003-02-28
EA200200518A1 (ru)	2002-10-31
AP2002002496A0 (en)	2002-06-30
PL355261A1 (en)	2004-04-05
AR029189A1 (es)	2003-06-18
EP1225866A2 (fr)	2002-07-31
TR200201211T2 (tr)	2002-08-21
MXPA02004350A (es)	2002-11-07
HK1049107A1 (zh)	2003-05-02
WO2001032127A2 (fr)	2001-05-10

Publication	Publication Date	Title
US20050070514A1 (en)	2005-03-31	Therapies for treating respiratory diseases
JP3002117B2 (ja)	2000-01-24	生物起原のエストロゲン成分を含む避妊／ホルモン置換のための医薬
AU2019254680B2 (en)	2024-10-10	Compounds and their uses for alleviating menopause-associated symptoms
CZ219196A3 (en)	1996-12-11	Application of mometasonfuorate aqueous suspension for preparing a medicament for effective intranasal treatment of nasal allergy
US20040176419A1 (en)	2004-09-09	Composition comprising a pde-4 inhibitor and h1-receptor antagonist and the use thereof for the manufacture of a medicament for the treatment of respiratory diseases
JP2005508963A (ja)	2005-04-07	喘息を治療するためのサルメテロールとフルチカゾンプロピオネートを含む医薬の組み合せ
TWI242431B (en)	2005-11-01	Pharmaceutical compositions for treating pulmonary diseases
US20040219137A1 (en)	2004-11-04	Method for reducing exacerbations associated with COPD
CA2417336A1 (fr)	2002-02-07	Procede pour reduire les exacerbations associees a la bpco
US20040214805A1 (en)	2004-10-28	Method and compositions for treating pulmonary diseases
JP2014515360A (ja)	2014-06-30	フルチカゾンを含む鼻用医薬製剤
AU2004205324A1 (en)	2004-09-23	Method and compositions for treating pulmonary diseases
JP2004500431A (ja)	2004-01-08	（ｒ，ｒ）−ホルモテロール及びロフレポニドを含む医薬組成物
EP1261331A1 (fr)	2002-12-04	Procede et compositions permettant de traiter les maladies fibrosantes
AU2003288169B2 (en)	2010-01-07	Synergistic combination comprising roflumilast and (R,R) -formoterol
US20030018071A1 (en)	2003-01-23	Method and compositions for treating fibrotic diseases
Pessayre et al.	2008	Features and mechanisms of druginduced liver injury
JP2004500436A (ja)	2004-01-08	呼吸器用組成物
CN115697346A (zh)	2023-02-03	适应障碍的治疗
HK40088154A (zh)	2023-09-22	适应障碍的治疗
AU2002310620A1 (en)	2003-01-08	Composition comprising a PDE-4 inhibitor and H1-receptor antagonist and the use thereof for the manufacture of a medicament for the treatment respiratory diseases
MX2011003726A (es)	2011-08-17	Metodos para tratar sintomas vasomotores en pacientes castrados que padecen cancer prostatico con acetato de ciproterona en dosis bajas.
AU2022415324A1 (en)	2024-07-04	Levonorgestrel butanoate formulation and methods relating thereto